Management  ˇC  Organization  ˇC  Company Milestone


Research and Development
ˇ@ Honest Stability & Inspirational Creativity
Excellent trained professional local and foreign talents with a commitment for constant breakthrough and innovation in mirroring word-class producersˇ¦ leading and remarkable R&D findings consistently, many of the core capabilities instilled have continued to fuel Taiwan Biotech Co., Ltd.
Active Pharmaceutical Ingredients Development
1. The development of Cephalospornic antibiotics and intermediaries; especially, Cephalexin has been certified by the U.S.FDA in 1994.
2. R&D leading high-end drug stocks focusing on treatment arthritis, osteoporosis, BPH, and cardiovascular diseases.
3. Developing ingredients and intermediaries by ferment method
Pharmaceutical Finished & Biotech Related Products Development:
1. Chinese herbal Product R&D
Researching and developing methods including extraction, purification, and formula development help bring natural substances and Chinese herbal into the domain of health food and drugs
2. Controlled release drugs
A controlled release drugs have been developed to excel the quality of drug dispensing.
3. Sterile formulation development
Backed by professional know-how and the unique processing equipment are adopted for leading sterile formulas research, produced by the automated PE Blowing-filling-sealing.
4. Dialysis treatment drugs
Developing most comprehensive dialysis drugs of in ensemble for the local market.
5. Contact lens solution and ophthalmic drugs
The unit dose package formula to improve the usage quality and easy to use.
6. Oral hygiene products
The supplying of school children to prevent dental caries used in mouthwash and related products
7. BE drug development
78 products have till 2005 been BE tested and certified.
Technical collaboration pact:
ˇ@ A technical collaboration pact working with the U.S. pharmaceutical development firm, Medinox, has yield a series of nitro oxide based and internal disease inhibiting drugs, designed to combat septic shocks, adult respiratory arrest, diabetes, and so forth.

ˇ@ ˇ@
ˇ@ Production
Innovative Resolution & Quality Insistence
Taiwan Biotech Co., Ltd. heeds the government development policy by upgrading itself from a GMP certified manufacture to cGMP in 2005 and our products have accredited with the National Pharmaceutical Quality Award.

The Taoyuan main production plant
The Taoyuan plant encompasses an expansive 324,000 square foot facility that houses four production plants including the parenteral plant, BFS (Blow-Fill-Seal) parenteral plant, solid product manufacturing plant and TDDS (Transdermal Drug Delivery System) plant.

The parenteral plant marks the longest running operations in company history as it began from the earlier daysˇ¦ production of glass bottles and injection syringes to the present dayˇ¦s fully automated operations for producing perfect injection fluid, noticeably of the 500 c.c. injectable fluid. Manufactured under the automated KT production line brought in from Japan offers a fully automated production process from ultrasonic rinsing, auto filling and capping, sterilization, automatic foreign particle detection, automatic labeling, and boxing. The hemo-dialysis fluid produced by the parenteral plant with high standard and production know-how share more than 45% of the market demand.

In 1979, we took the lead in Asia for introducing a Bottle Pack machine from Rommelag Switzerland, offering an automatic production from PE blowing, filling, and sealing to produce sterile parenteral agents including injection, inhalation solution, eye care and ophthalmic treatment solution which remained uncontested across Taiwan. All these products that come with the advantages of sterile, unit dosage, free of preservatives and easy carry, the PE material used for container is of high medical grade, safe and free of toxicity to warrant higher safety than the conventional glass ampoule and sparing the risk of getting hurt by glass cuts which happened sometime when glass ampoule is used.

The solid product manufacturing plant is firmˇ¦s emerging latecomer, supported by automation, high capacity output and with excellent quality to produce 78 BE products before 2005, Taiwan Biotech Co., Ltd. installed a high speed encapsulation machine equipped with weight checker from Bosch, Germany, which could produce 150,000 capsules per hour with an individual weight checking to ensure weight of each capsule is a control range.

The TDDS (Transdermal Drug Delivery System) plant mainly produces suspend release patch, the nicotine patch that currently launched in the market is the leading formula developed by Taiwan Biotech Co., Ltd. in synchronization with premier world producer, and is the only one containing medicine in Taiwan.

Biotech Production Plant at the Hsinchu Science-based Industrial Park
Plant located in the Hsinchu Science-based Industrial Park concentrates in the research and
development of health beneficial biotech foods and Chinese herbal medicine, noticeably of the
successful extraction of active substances derived from the American ginseng working with the
Pharmaceutical Technology Center that offers beneficial yield for gastrointestinal and bodily
health.
ˇ@
The Taoyuan API Plant
The Active Pharmaceutical Ingredients plant primarily produces Cephalosporin antibiotics and intermediate, noticeably of the Cephalexin that has been certified by the U.S. FDA in 1994.


The Kuan Yin Plant
The newly acquired plant provides cephalosporin products in form of tablets, capsules, and injections which support Taoyan main plant in mapping out a comprehensive product portfolio. Also the new plant is fitting the world trend of individual production site of antibiotics.

The Veterans Pharmaceutical Plant
Recently acquired the factory management authority, mainly supplies gastrointestinal and respiratory treatment drugs, and skin improvement products.

ˇ@
Marketing
Global Construction & Integrated Competitiveness
ˇ@
1. Product Line
The company's business divided by product groups encompasses,
(1) Drugs formulas -
ˇ@ Acting and affecting on the central nervous, cardiovascular, respiratory, gastrointestinal, urogenital, and muscle-skeletal systems. Anti-microorganisms, anti-diabetes, syrups, amino based titrations and injections, vitamin injections, X ray contrast media, individually packaged oral or ophthalmologic agents, and orphan drugs.
(2) Health care products -
  Health enhancing foods offer immunity enhancement and weight control, and the nicotine patches that help smokers quit smoking.
(3) Chinese herbal medicine -
ˇ@ Developed through biotech R&D is intended for gastrointestinal and liver enhancement and blood concentration regulating.
(4)  Medical Devices -
  ZOLL M-Series Defibrillator, ZOLL AED PLUS, ZOLL AutoPulse; Hologic SAHARA Ultrasonic Bone Sonometer; We-Gene Autonomic Nerve System Analyzer (ANSA)
(5) Bulk drug -
ˇ@ Cephalosporin based antibiotics and intermediaries, and treatment arthritis, osteoporosis, prostates hypertrophy, allergy, and hypertension regulating drugs.
2. Distribution :
Consist of medical treatment outlets, pharmacies, eyewear companies, and convenient stores.
3. Global-market Orientation
The company has since 1996 installed a global trading enterprise development division in charge of promoting export of house products and its painstaking operations over the past five years has yielded a dynamic sales network of steady growth across Japan, Southeast Asia, Mainland China, and North America. With expectation for the future, the company continues expanding its pharmaceutical products to world markets and takes a two-way exchange of innovative foreign biotech know-how and fine products to excel the companyˇ¦s R&D know-how and improve its overall competitiveness.
4. Sales Force:
The companyˇ¦s sales training team consists of professional managers, over 20 licensed pharmacists and nutritionists backed by a comprehensive sales education and training system, offering routine training sessions that have yielded more than 200 top-notch trained sales pros who are committed to customer first service orientation in offering individual & professional services.



Contact : International Business Department
Email : trade-a@sintong.com
Address :
No.22,  Jie Shou Road, Taoyuan, Taiwan
Tel : +886-3-361-2131
Fax : +886-3-367-0029
Taipei Office : +886-2-2351-9839